Agilus Diagnostics to withdraw DRHP filed with market regulator Sebi
14 February 2024
Diagnostic services provider Agilus Diagnostics announced on Tuesday that it will withdraw its draft red herring prospectus (DRHP) filed with the Securities and Exchange Board of India (Sebi). After the decision was announced late Tuesday night, Fortis Healthcare stock fell 3.23 percent in morning trade around 11 am. The company said in its regulatory filing that the decision to withdraw the DRHP has been taken due to commercial considerations and in consultation and mutual agreement with the private equity investors of Agilus and its board of directors, the company said in a regulatory filing on the Bombay Stock Exchange (BSE).
Diagnostic services provider Agilus Diagnostics announced on Tuesday that it will withdraw its draft red herring prospectus (DRHP) filed with the Securities and Exchange Board of India (Sebi). After the decision was announced late Tuesday night, Fortis Healthcare stock fell 3.23 percent in morning trade around 11 am. The company said in its regulatory filing that the decision to withdraw the DRHP has been taken due to commercial considerations and in consultation and mutual agreement with the private equity investors of Agilus and its board of directors, the company said in a regulatory filing on the Bombay Stock Exchange (BSE).
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.
Pre Ipo
Upcoming IPO
Unicorn
Planify Enterprises Private Limited
Planify Capital Limited
Licensed By
Mutual Fund License No.:
ARN-164419
IRDA Code (1):
ABLIC1003123454
IRDA Code (2):
ABLIC1003131639
Startup India Certificate No.:
DIPP93786
Other Websites
ⓒ 2016-2026 Planify. All rights reserved, Built with
in India
